Form 4: GRAIL Director William Chase Awarded Over 6,000 Restricted Stock Units to Align Interests

GRAIL, Inc. Director William J. Chase has been granted 6,082 restricted stock units (RSUs) valued at $41.1 per unit, aligning his interests with long-term shareholder value.

Summary

• William J. Chase, a Director of GRAIL, Inc., was awarded 6,082 restricted stock units (RSUs) on May 29, 2025.
• These RSUs were granted under the company's 2024 Equity Incentive Plan.
• Each RSU represents the right to receive one share of GRAIL common stock, valued at $41.1 per unit at the time of grant.
• The RSUs are scheduled to vest in full on the earlier of May 29, 2026, or the date of the next annual meeting of the Company's stockholders, contingent upon Mr. Chase's continued service.
• Following this transaction, Mr. Chase beneficially owns 35,782 shares of common stock.

Sentiment

Score: 7

Explanation: The grant of restricted stock units to a director is generally a positive signal as it aligns the director's interests with the long-term performance of the company and shareholder value. It's a standard incentive mechanism.

Positives

• The grant of restricted stock units to a director aligns management's interests with long-term shareholder value.
• The award incentivizes continued service and performance from a key board member.
• The transaction increases the director's direct beneficial ownership in the company, demonstrating confidence.

Negatives

• This transaction is an equity award, not a direct cash purchase by the director, meaning no immediate cash inflow from the director into the company.
• The vesting is subject to continued service, which is standard but means the shares are not immediately owned outright.

Future Outlook

NA

Industry Context

This transaction is a standard form of equity compensation for directors in the biotechnology and healthcare industry, aiming to align their long-term interests with the company's performance and shareholder returns. It reflects common corporate governance practices for incentivizing leadership.

Comparison to Industry Standards

• The grant of restricted stock units (RSUs) to directors is a common practice across publicly traded companies, particularly in the high-growth biotechnology sector, to attract and retain talent and align their interests with long-term shareholder value.
• The vesting schedule, tied to continued service and a specific future date or the next annual meeting, is typical for such equity awards, similar to practices seen at companies like Illumina (ILMN) or Guardant Health (GH) for their board members.
• The value of the award ($41.1 per unit) reflects the company's stock price at the time of grant, which is standard for RSU awards.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of RSUs to a director aims to align the director's interests with shareholders, potentially leading to better long-term decision-making focused on increasing shareholder value.
• Employees: While not directly impacting all employees, the use of equity incentive plans can signal a commitment to performance-based compensation, which might indirectly influence employee morale and retention strategies.

Next Steps

• The restricted stock units are expected to vest on the earlier of May 29, 2026, or the date of the next annual meeting of the Company's stockholders, subject to continued service.

Key Dates

Recommendation

Keywords

GRAIL Inc., GRAL, SEC Form 4, Restricted Stock Units, RSU, Insider Ownership, Equity Incentive Plan, Director Compensation, Stock Award, Corporate Governance